- CEO
- Tai Sen Soong
- Full Time Employees
- 15
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- No. 225, Peihsin Road New Taipei CHA Taiwan 23143
- IPO Date
- Apr 24, 2017
- Business
- Senhwa Biosciences, Inc. (6492.TWO) is a clinical-stage biotechnology company focused on developing next-generation DNA Damage Response (DDR) therapeutics and targeted agents for cancer treatment, rare diseases, and related indications. The company advances a pipeline of first-in-class small molecule drugs, including its lead candidate Pidnarulex (CX-5461), a G-quadruplex stabilizer targeting solid tumors such as ovarian cancer, breast cancer, MYC-aberrant B-cell lymphoma, refractory microsatellite stable colorectal cancer, and hematologic malignancies; and Silmitasertib (CX-4945), a Casein Kinase 2 inhibitor for cholangiocarcinoma, basal cell carcinoma, medulloblastoma, and neuroblastoma. Clinical trials for these programs span Phase 1 through Phase 2 across monotherapy, combination with immunotherapy (including PD-1 inhibitors), and antibody-drug conjugates, conducted in collaboration with partners in the United States, Canada, Australia, South Korea, and Taiwan; additional exploratory applications include HIV functional cure and immune microenvironment modulation to convert cold tumors to hot tumors.
Founded in 2012 and headquartered at 10F, No. 225, Sec. 3, Peihsin Rd., Hsintien Dist., New Taipei City, Taiwan, with a key operational subsidiary in San Diego, California, USA, Senhwa Biosciences conducts global R&D and leverages service providers across North America, Asia, Australia, and Europe to advance its programs toward proof-of-concept and commercialization. The company listed on the Taipei Exchange in 2017 and targets unmet needs in oncology, including HRD-deficient cancers, MYC-driven lymphomas, and pediatric rare tumors, with orphan drug and rare pediatric disease designations for multiple CX-4945 indications providing regulatory incentives such as tax credits and market exclusivity.
Recent developments include a five-year collaboration agreement with the U.S. National Cancer Institute (NCI) under the NIH's NExT program in 2024 to support CX-5461 advancement in MYC-driven lymphoma and cross-cancer indications, with IND submissions and patient enrollment underway; partnerships with the Pediatric Brain Tumor Consortium (PBTC) and others for medulloblastoma trials; and strategic alliances with global PD-1 leaders announced in October 2025 to combine CX-5461 with immunotherapy for broader oncology applications. In June 2025, Senhwa highlighted breakthroughs at its annual shareholders' meeting, including long-term survival data in pancreatic cancer patients and plans for trial completion and out-licensing in 2026; the company also explores HIV applications for CX-4945 based on its immune-modulating effects. These initiatives reflect Senhwa's shift toward combination therapies, NCI-sponsored expansions, and global licensing to enhance pipeline value.